SLC5A2 and cardiomyopathy: For HFpEF, the EMPEROR-Preserved and DELIVER trials revealed that SGLT2 inhibitors not only reduced the combined endpoint of cardiovascular death and HHF but also modestly improved patient-reported symptoms, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) [144].